60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
Investing.com -- Genenta Science SpA ADR (NASDAQ:GNTA) stock jumped 12.5% in premarket trading Monday following the company’s update on its ongoing TEM-GBM study for glioblastoma multiforme patients with unmethylated MGMT gene promoter.
The clinical-stage biotechnology company reported that 44% of patients in the study reached 18-month survival, up from 38% reported in April. Two-year survival rate remained at 29% and median overall survival held steady at 17 months, which compares favorably to historical cohorts showing approximately 14% two-year survival and 13-15 months median overall survival with standard care.
Notably, the company highlighted one patient who reached three years of survival following treatment with Temferon without requiring additional therapeutic interventions during that period. This patient recently completed a 3.5-year follow-up visit after undergoing a second surgery due to disease progression detected at the three-year mark.
The study also provided preliminary immune observations suggesting that bone-marrow-derived myeloid cells can reach tumor sites and deliver immunotherapeutic payloads as intended by the platform design. These findings, while exploratory, are helping to inform the broader development of Temferon and the company’s cell-based delivery technology.
Genenta reported approximately $30 million in cash and short-term investments as of November 1, following the closing of its October 27 registered direct offering.
The company’s Temferon is a cell-based platform for targeted delivery of therapeutic payloads in oncology, with the glioblastoma study representing its first clinical application.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.